Rise from compromise to confidence

Kadcyla®
trastuzumab emtansine

Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive eBC who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.[1]

Dosing and Administration

- In the adjuvant setting, Kadcyla should be administered for a total of 14, 3-week cycles, or until disease recurrence or unmanageable toxicity.[1]

Kadcyla	First infusion	Every 3 weeks for up to 14 cycles
	3.6 mg/kg bodyweight adminstered over 90 minutes	3.6 mg/kg bodyweight adminstered over 30 minutes

- Kadcyla is administered as an IV infusion.[1]
- Patients should be observed during the infusion and for atleast 90 mins following the initial infusion fever, chills and other infusion related reactions. The infusion site should be monitored for possible SC infiltration during administration.[1]
- If the prior infusion was well tolerated, subsequent doses of Kadcyla may be administered as 30-minute infusions. Patients should be observed during the infusion and for at least 30 minutes after infusion.[1]
- In order to prevent medicinal product errors, it is important to check the vial labels to ensure that the medicinal product being prepared is trastuzumab emantasine and not trastuzumab.[1]
- Kadcyla allows oncologists to adapt adjuvant therapy based on patients' neoadjuvant response.[2]

* HER2- Human Epidermal Growth Factor Receptor 2; eBC- Early Breast Cancer; IV- Intravenous; SC- Subcutaneous

References:
1. Kadcyla Summary of Product Characteristics.
2. Scottish Medicines Consortium. SMC2298. November 2020.

Warning: To be sold by retail on the prescription of an "Oncologist" only

Kindly use the QR code/ click on the link for the latest Prescribing Information (PI). For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.

http://bit.ly/Roche_Kadcyla_PI

Full prescribing information available on request. For scientific information on Roche Medicinal products, please write to india medinfo@roche.com. For all suspected Adverse Event / Special Situations and Other Case Type Reports*/ Product Complaints associated with the use of a Roche medicinal product please report the same to india.drugsafety@roche.com"

*Pregnancy/Breastfeeding, use in Pediatric/Elderly population, Lack of Efficacy, Overdose, Misuse, Abuse, Off Label Use, Medication Error (including Intercepted Medication Error and Potential Medication Error), Occupational Exposure, data related to a Suspected Transmission of an Infectious Agent via a Medicinal Product (STIAMP), Drug Interaction, Falsified Medicinal Products (whether suspected or confirmed) and suspected AEs from class action lawsuits

This promotional input is not valid after 28/06/2024

Disclaimers:

For all Adverse Events/Special Situation Reports with Roche Medicinal Products please report the same to india.drugsafety@roche.com within one business day/24 hours.
For Scientific information on Roche Medicinal Product please write to india.medinfo@roche.com.
For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only. Full prescribing information is available on request.

M-IN-00002905

Marketed in India by:
Roche Products (India) Pvt. Ltd.
146-B, 166 A, Unit No. 7, 8, 9, 8th Floor, R City Office, R City Mall, Lal Bahadur Shastri Marg, Ghatkopar, Mumbai - 400 086
Maharashtra; Tel No. +91 22 50457300; Fax No. +91 22 50457301

Mail this to me: